Multiple myeloma: epidemiology and therapeutic options.
Myeloma remains an incurable disease, but its management has significantly improved with the introduction of novel treatment agents. Variations in both disease manifestation and patient response to treatment have personalized approaches to care.
Tuscano
Joseph M
JM
Department of Internal Medicine, Division ofHematology and Oncology, University of California-Davis Cancer Center, Sacramento, USA.
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols; D002908:Chronic Disease; D003907:Dexamethasone / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D008495:Medical Oncology / Q000639:trends*; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D010346:Patient Care Management; D011379:Prognosis; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide